Taking stock of the drug industry, from the lab to the medicine chest

September 20, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Erin Lubin/T1International Opinion: How I fought Big Pharma on insulin prices — and won Patient advocacy groups can score big victories if they avoid the trap of taking money from their opponents, writes T1international founder. By Elizabeth Pfiester STAT+ | FTC sues big 3 PBMs for 'artificially inflated' insulin prices caused by 'perverse' rebating The FTC argued CVS Caremark, Cigna's Express Scripts, and UnitedHealth's OptumRx 'lined their pockets' at the expense of patients. By Ed Silverman STAT+ | Ginkgo Bioworks bets on protein AI model and data generation to turn struggling company around Ginkgo executives say its new offerings provide an opportunity where it can clearly compete. But experts and analysts aren't so sure. By Brittany Trang and Jason Mast Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman STAT+ | Cassidy seeks to exempt small biotechs from Medicare drug price negotiation  The proposal shows how the GOP may attempt to rein in one of Biden's signature accomplishments. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser